Neuropeptides for Alzheimer's Disease Research

Alzheimer’s Disease

As the sixth leading cause of death in the United States, Alzheimer’s disease, a chronic neurodegenerative disease, affects more than 5 million people in the United States alone. It is estimated that Alzheimer’s disease and other dementias will cost $236 million in medical care in 2016. Alzheimer’s disease is a progressive brain disorder that causes problems with memory, thinking, and behavior. Extracellular amyloid plaques, caused by the Amyloid β-Protein, and intracellular neurofibrillary tangles are hallmark features of the disease.1

The buildup of plaques in the brain from Amyloid β-Protein cause inflammation and neurodegeneration. Recently, P. Bhattarai and his team in Dresden, Germany, have discovered that, in zebrafish, Interleukin-4 (IL-4) is activated by neurons in response to Amyloid β-Protein, resulting in increased neuron proliferation. This discovery can lead to further research in treating human neural degradation due to Alzheimer’s.2 If scientists can figure out how to activate IL-4 in humans, the lost neurons can possibly be replaced.

In families where early-onset Alzheimer’s disease is prevalent, it is thought that a mutation in the PSEN1 gene creates a defective presenilin-1 protein. This in turn causes a disruption in the function of the γ-secretase complex.3 DAPT is an inhibitor of presenilin-dependent γ-secretase which has been shown to block Amyloid β-Protein production in neuronal cultures.4

 IGS-3641-PI-DAPT.jpg

 DAPT (IGS-3641-PI)

 

References

  1. http://www.alz.org/facts/
  2. P. Bhattarai, et al., Cell Reports, 17, 941 (2016). Retrieved from http://www.cell.com/cell-reports/pdf/S2211-1247(16)31331-6.pdf
  3. https://ghr.nlm.nih.gov/gene/PSEN1#conditions
  4. A.Y. Kornilova, et al, J. Biol. Chem., 278, 16470 (2003). Retrieved from http://www.jbc.org/content/278/19/16470.long

You can also view our products for Alzheimer's research in the online catalog here.

Authors from Peptides International

Related Articles